The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age

BMC Geriatrics

Volumn 12, Issue , 2012, Pages

  Jackson, Robert L ^a   Hunt, Barbara ^a   MacDonald, Patricia A ^a  

^a TAKEDA PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGOUT AGENT; BIOLOGICAL MARKER; FEBUXOSTAT; THIAZOLE DERIVATIVE; URIC ACID; XANTHINE OXIDASE;

AGED; ARTICLE; BLOOD; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; ENZYMOLOGY; FEMALE; GOUT; HUMAN; HYPERURICEMIA; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COHORT STUDIES; DOUBLE-BLIND METHOD; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; MALE; THIAZOLES; TREATMENT OUTCOME; URIC ACID; XANTHINE OXIDASE;

EID: 84858598703     PISSN: None     EISSN: 14712318     Source Type: Journal    
DOI: 10.1186/1471-2318-12-11     Document Type: Article

References (49)

1. Gout in ambulatory care settings in the United States. Krishnan E, Lienesch D, Kwoh CK, J Rheumatol 2008 35 498 501 18260174 (Pubitemid 351374428)
2. Health, United States, 2009: With special feature on medical technology. National Center for Health Statistics, Hyattsville: Centers for Disease Control. U.S. Department of Health and Human Services 2010
3. Gout: six-year follow-up on probenecid (benemid) therapy. Bartels EC, Matossian GS, Arthritis Rheum 1959 2 193 202 10.1002/1529-0131(195906)2: 3<193::AID-ART1780020302>3.0.CO;2-8 13662213
4. Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease. Kang DH, Nakagawa T, Semin Nephrol 2005 25 43 49 10.1016/j.semnephrol.2004.10.001 15660334 (Pubitemid 40128148)
5. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Hande KR, Noone RM, Stone WJ, Am J Med 1984 76 47 56 6430077 (Pubitemid 14216359)
6. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. Dalbeth N, Kumar S, Stamp L, Gow P, J Rheumatol 2006 33 1646 1650 16783857 (Pubitemid 44168841)
7. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S, Becker MA, Life Sci 2005 76 1835 1847 10.1016/j.lfs.2004. 10.031 15698861 (Pubitemid 40215224)
8. Uloric Full Prescribing Information. Deerfield, IL: Takeda Pharmaceuticals North America, Inc. 2011
9. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Becker MA, Kisicki J, Khosravan R, Wu J, Mulford D, Hunt B, MacDonald P, Joseph-Ridge N, Nucleosides Nucleotides Nucleic Acids 2004 23 1111 1116 10.1081/NCN-200027372 15571211 (Pubitemid 39625877)
10. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. Khosravan R, Kukulka MJ, Wu JT, Joseph-Ridge N, Vernillet L, J Clin Pharmacol 2008 48 1014 1024 10.1177/0091270008322035 18635756
11. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. Khosravan R, Grabowski BA, Mayer MD, Wu JT, Joseph-Ridge N, Vernillet L, J Clin Pharmacol 2006 46 88 102 10.1177/0091270005282634 16397288 (Pubitemid 43021717)
12. PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Hoshide S, Takahashi Y, Ishikawa T, Kubo J, Tsuchimoto M, Komoriya K, Ohno I, Hosoya T, Nucleosides Nucleotides Nucleic Acids 2004 23 1117 1118 10.1081/NCN-200027377 15571212 (Pubitemid 39625878)
13. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Becker MA, Schumacher HR, Espinoza LR, Wells AF, Macdonald P, Lloyd E, Lademacher C, Arthritis Res Ther 2010 12 63 10.1186/ar2978 20370912
14. Preliminary criteria for the classification of the acute arthritis of primary gout. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF, Arthritis Rheum 1977 20 895 900 10.1002/art.1780200320 856219
15. Prediction of creatinine clearance from serum creatinine. Cockcroft DW, Gault MH, Nephron 1976 16 31 41 10.1159/000180580 1244564
16. Predictability of creatinine clearance estimates in critically ill patients. Robert S, Zarowitz BJ, Peterson EL, Dumler F, Crit Care Med 1993 21 1487 1495 10.1097/00003246-199310000-00016 8403957 (Pubitemid 23312482)
17. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Becker MA, MacDonald PA, Hunt BJ, Lademacher C, Joseph-Ridge N, Nucleosides Nucleotides Nucleic Acids 2008 27 585 591 10.1080/15257770802136032 18600509 (Pubitemid 351948555)
18. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Wortmann RL, Macdonald PA, Hunt B, Jackson RL, Clin Ther 2010 32 2386 2397 10.1016/j.clinthera.2011.01.008 21353107
19. Mechanisms of uric acid crystal-mediated autoinflammation. Martinon F, Immunol Rev 2010 233 218 232 10.1111/j.0105-2896.2009.00860.x 20193002
20. Clinical efficacy and safety of successful long-term urate lowering with febuxostat or allopurinol in subjects with gout. Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C, J Rheumatol 2009 36 1273 1282 10.3899/jrheum.080814 19286847
21. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Schumacher HR Jr, Becker MA, Lloyd E, MacDonald PA, Lademacher C, Rheumatology (Oxford) 2009 48 188 194
22. Epidemiology of gout: is the incidence rising? Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE, J Rheumatol 2002 29 2403 2406 12415600 (Pubitemid 35266034)
23. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R, J Rheumatol 2004 31 1582 1587 15290739 (Pubitemid 39006641)
24. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, Gabriel S, Hirsch R, Hochberg MC, Hunder GG, Jordan JM, Katz JN, Kremers HM, Wolfe F, Arthritis Rheum 2008 58 26 35 10.1002/art.23176 18163497
25. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Shoji A, Yamanaka H, Kamatani N, Arthritis Rheum 2004 51 321 325 10.1002/art.20405 15188314 (Pubitemid 38725128)
26. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A, Arthritis Rheum 2002 47 356 360 10.1002/art.10511 12209479 (Pubitemid 34856121)
27. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Perez-Ruiz F, Liote F, Arthritis Rheum 2007 57 1324 1328 10.1002/art.23007 17907217 (Pubitemid 47585481)
28. Renal function in gout: long-term treatment effects of febuxostat. Whelton A, Macdonald PA, Zhao L, Hunt B, Gunawardhana L, J Clin Rheumatol 2011 17 7 13 21169856
29. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Choi HK, De Vera MA, Krishnan E, Rheumatology (Oxford) 2008 47 1567 1570 10.1093/rheumatology/ken305
30. High serum uric acid as a novel risk factor for type 2 diabetes. Dehghan A, van Hoek M, Sijbrands EJ, Hofman A, Witteman JC, Diabetes Care 2008 31 361 362 17977935 (Pubitemid 351213351)
31. Independent impact of gout on mortality and risk for coronary heart disease. Choi HK, Curhan G, Circulation 2007 116 894 900 10.1161/CIRCULATIONAHA. 107.703389 17698728 (Pubitemid 47300913)
32. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. De Vera MA, Rahman MM, Bhole V, Kopec JA, Choi HK, Ann Rheum Dis 2010 69 1162 1164 10.1136/ard.2009.122770 20124358
33. Gout and the risk of acute myocardial infarction. Krishnan E, Baker JF, Furst DE, Schumacher HR, Arthritis Rheum 2006 54 2688 2696 10.1002/art.22014 16871533 (Pubitemid 44208638)
34. Long-term cardiovascular mortality among middle-aged men with gout. Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH, Arch Intern Med 2008 168 1104 1110 10.1001/archinte.168.10.1104 18504339 (Pubitemid 351749228)
35. Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout. Krishnan E, Rheumatology (Oxford) 2010 49 1229 1238 10.1093/rheumatology/keq037
36. Gout in the elderly-a population health study. Hanly JG, Skedgel C, Sketris I, Cooke C, Linehan T, Thompson K, van Zanten SV, J Rheumatol 2009 36 822 830 10.3899/jrheum.080768 19286852
37. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Keenan RT, O'Brien WR, Lee KH, Crittenden DB, Fisher MC, Goldfarb DS, Krasnokutsky S, Oh C, Pillinger MH, Am J Med 2011 124 155 163 10.1016/j.amjmed.2010.09.012 21295195
38. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Caspi D, Lubart E, Graff E, Habot B, Yaron M, Segal R, Arthritis Rheum 2000 43 103 108 10.1002/1529-0131(200001)43:1<103::AID- ANR13>3.0.CO;2-C 10643705 (Pubitemid 30368218)
39. Cardiovascular drugs and serum uric acid. Reyes AJ, Cardiovasc Drugs Ther 2003 17 397 414 15107595 (Pubitemid 38339910)
40. Thiazide diuretics and the initiation of anti-gout therapy. Gurwitz JH, Kalish SC, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J, J Clin Epidemiol 1997 50 953 959 10.1016/S0895-4356(97)00101-7 9291881 (Pubitemid 27423526)
41. Comparison of drug adherence rates among patients with seven different medical conditions. Briesacher BA, Andrade SE, Fouayzi H, Chan KA, Pharmacotherapy 2008 28 437 443 10.1592/phco.28.4.437 18363527 (Pubitemid 351466455)
42. Disease-related and all-cause health care costs of elderly patients with gout. Wu EQ, Patel PA, Yu AP, Mody RR, Cahill KE, Tang J, Krishnan E, J Manag Care Pharm 2008 14 164 175 18331118 (Pubitemid 351453817)
43. Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? Wu EQ, Patel PA, Mody RR, Yu AP, Cahill KE, Tang J, Krishnan E, J Rheumatol 2009 36 1032 1040 10.3899/jrheum.080487 19369467
44. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, Bakst AW, Mayo Clin Proc 2006 81 925 934 10.4065/81.7.925 16835972 (Pubitemid 43993484)
45. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Solomon DH, Avorn J, Levin R, Brookhart MA, Ann Rheum Dis 2008 67 609 613 17728328 (Pubitemid 351571922)
46. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liote F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentao J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gorska I, Ann Rheum Dis 2006 65 1312 1324 10.1136/ard.2006.055269 16707532 (Pubitemid 44620440)
47. A randomised controlled trial on the efficacy and tolerability with dose-escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Reinders MK, Haagsma C, Jansen TL, van Roon EN, Delsing J, van de Laar MA, Brouwers JR, Ann Rheum Dis 2009 68 892 897 10.1136/ard.2008.091462 18633127
48. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Stamp LK, O'Donnell JL, Zhang M, James J, Frampton C, Barclay ML, Chapman PT, Arthritis Rheum 2011 63 412 421 10.1002/art.30119 21279998
49. Managing gout: how is it different in patients with chronic kidney disease? El-Zawawy H, Mandell BF, Cleve Clin J Med 2010 77 919 928 10.3949/ccjm.77a.09080 21147946